Journal of Immunology Research / 2015 / Article / Tab 2

Research Article

Osteoprotegerin Polymorphisms in a Mexican Population with Rheumatoid Arthritis and Generalized Osteoporosis: A Preliminary Report

Table 2

Clinical characteristics of study patients.

Characteristic = 81

Age (years), median (range)49.9 (21–79)
Menopausal, (%)43 (53.1)
Weight (kg), median (range)65.8 (43–94)
BMI, median (range) 26.87 (18–38)
Oral contraceptives use, (%) 41 (50.6)
Current smoker, (%)17 (21)
Family history of fractures (%)6 (7.4)
Alcohol consumption 3 or more units/day, (%) 3 (3.37)
Duration of RA (years), median (range)11.8 (1.5–35)
DAS-28 score, median (range)3.8 (0–6.7)
Global functional status III-IV, (%)7 (7.8)
HAQ-DI score, median (range)0.7 (0–2.8)

Medications (%)

Glucocorticoid72 (88.9)
Prednisone dosage (mg/day), median (range)4.4 (0–10)
Methotrexate56 (70.9)
Sulfasalazine39 (49.4)
Chloroquine27 (34.2)
Azathioprine25 (31.6)
D-Penicillamine10 (12.7)
Biologic agents 8 (10.1)

BMD (WHO classification) (%)

Normal23 (33.3)
Osteopenia/osteoporosis46 (66.7)

BMI: body mass index, RA: rheumatoid arthritis, DAS-28: disease activity score, HAQ-DI: health assessment questionnaire-disability index, BMD: bone mineral density, and WHO: World Health Organization.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.